Practical Considerations for Implementation of 177 Lu-DOTATATE Neuroendocrine Tumor Treatment Programs

Journal of nuclear medicine technology

article

Diane K. Soulek¹  Molly E. Martin¹  Nic J. Mastascusa¹  Stephen A. Graves¹ 

[1] Department of Radiology, University of Iowa

关键词: neuroendocrine tumor;    177Lu-DOTATATE;    somatostatin receptor;    PRRT;    dosimetry;   

DOI  :  10.2967/jnmt.122.263813

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The 2018 Food and Drug Administration approval of 177Lu-DOTATATE for the treatment of somatostatin receptor–positive neuroendocrine tumors (NETs) represents a paradigm-shifting approach to cancer treatments around the globe. Gastroenteropancreatic NETs overexpress the somatostatin subtype receptor 2, which is now exploited for receptor-based imaging and therapy, thus generating significant progress in the diagnosis and treatment of this orphan disease. The recent Food and Drug Administration approval of receptor-based PET radiopharmaceuticals and a new peptide receptor radiopharmaceutical therapy, 177Lu-DOTATATE, has dramatically impacted NET patient management. The focus of this paper is to review clinical considerations associated with implementing a 177Lu-DOTATATE program. We review receptor-based NET radiopharmaceuticals; 177Lu-DOTATATE patient selection criteria; administration methods; clinical, regulatory, and radiation safety considerations; technical factors; tissue dosimetry; and reimbursement guidelines.

【 授权许可】

CC BY